New medicine is arriving faster than the safety net can hold it

Thursday is a study in mismatch. The tools that help are multiplying: drugs that blunt craving across five substances, paramedics starting treatment on the sidewalk. The things that keep people alive between doses keep getting pulled out from under them.

Today’s reporting

01Science & MedicineJun 25

The Clinic on Every Corner: Ketamine Is Treating Depression and Creating New Addictions Simultaneously

Ketamine clinics have grown from under 100 to more than 1,500 nationwide since 2015. Spravato now clears $2.3B annually. Meanwhile, ketamine use disorder is rising and the regulatory framework governing who can give it and to whom remains a patchwork. A look at the biology, the boom, and the blind spots.

The 60-second read

The craving drugs went broad. The clearest signal yet that GLP-1 medications (the Ozempic family) cut substance-use risk across five different drug classes at once, from alcohol to opioids. If you have white-knuckled a craving, the interesting part isn’t the chemistry. It’s that the thing quieting it wasn’t built for addiction at all.
Treatment stopped waiting for you to show up. In Florida, paramedics are starting buprenorphine at the scene: in the ambulance, on the sidewalk, the moment after an overdose is reversed. The old rule was that recovery begins when you walk through a clinic door. That rule is being quietly rewritten.
The supply got deadlier and the net got thinner in the same week. Carfentanil is back in more than one in ten fentanyl samples. At the same time, an insurance plan changing its mind is enough to push someone in stable recovery back toward a relapse. One of those is a chemistry problem. The other is a paperwork problem. They kill the same way.

What’s new in the field

Opioids

The deadliest story is the quietest one: carfentanil, roughly 100 times stronger than fentanyl, has resurfaced in the supply. On the policy side, a bill to let methadone be dispensed at the corner pharmacy is back in front of Congress, the kind of access change that sounds boring and isn’t. And Florida’s field-initiated buprenorphine programs keep posting numbers that challenge how we think about when treatment can start.

Stimulants

No pharmacotherapy has ever been approved for methamphetamine or cocaine use disorder, which is exactly why the GLP-1 cross-substance data, which includes a cocaine signal, is worth watching closely rather than hyping.

Depressants

The DEA placed a designer benzodiazepine into Schedule I, a first-of-its-kind move whose actual effect on anyone’s safety is a genuinely open question.

Dissociatives

The ketamine clinic on every corner is today’s lead: a market that has doubled in two years while the rules governing who can prescribe it and to whom stayed a patchwork. The same drug pulling people out of depression is creating a dependence problem few clinics are set up to catch.

The pulse

The word underneath a lot of the recovery community this week was whiplash. People are reading that a shot taken once a week can quiet a craving, and two headlines later, that a change in a benefits formula they never agreed to could undo years of steady ground. If that is you right now: the unsteadiness you’re feeling isn’t a character flaw, it’s an accurate read of a system that keeps moving the floor. You are not behind. You are paying attention. Hold the next right thing, not the whole staircase.

Arizona watch

Quiet on the state front this week. We’re keeping an eye on how AHCCCS and Maricopa County direct opioid-settlement dollars next. The field-treatment and pharmacy-access models making news elsewhere are exactly the kind of thing those funds could underwrite here.